Standards; Pharmaceutical/API Drug Impurities/Metabolites;
应用:
(2S)-2-(3-(Trifluoromethyl)phenyl)-N-((R)-1-(naphthalen-1-yl)ethyl)propan-1-amine, is an impurity of Cinacalcet (C441790), the first calcimimetic drug approved by the United States Food and Drug Administration for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.